Amgen (AMGN) Said to Make $7B Bid for Human Genome (HGSI) in 2010
Tweet Send to a Friend
Get Alerts AMGN Hot Sheet
Price: $105.81 +0.18%
Overall Analyst Rating:
NEUTRAL (= Flat)
Dividend Yield: 1.7%
Revenue Growth %: +3.7%
Overall Analyst Rating:
NEUTRAL (= Flat)
Dividend Yield: 1.7%
Revenue Growth %: +3.7%
Trade AMGN Now!
Amgen (Nasdaq: AMGN) might be looking like a winner early, but that wasn't the case two years ago.
Current product portfolio notwithstanding, reports out today have Amgen making a $35 per share bid for Human Genome (Nasdaq: HGSI) back in August 2010. Despite the seemingly rich offer -- Human Genome's stock peaked at about $32.50 -- the $7 billion bid was rejected.
Today, Amgen is ticking higher following stronger-than-expected results for its second quarter, EPS of $1.83 beating views by 29 cents. Product sales rose 8 percent and its pipeline is in shipshape. In fact, shares are up a minimum of 44 percent since 2010, while Human Genome stock has fallen 56 percent over the same span.
Last week, Human Genome finally caved, agreeing to a $14.25 per share deal with GlaxoSmithKline (NYSE: GSK), which values the company at about $3 billion, or far less than what it would have received from Amgen.
Hindsight is 20/2, though. Human Genome had Benlysta in the works, which it hoped would propel the company to new heights. FDA approval in March 2011 led to paltry sales and a drop in Human Genome shares.
With the latest takeover, Human Genome invited Amgen to make a bid...but to no avail.
Amgen shares are about 4 percent higher in early trading, while Human Genome is flat.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Current product portfolio notwithstanding, reports out today have Amgen making a $35 per share bid for Human Genome (Nasdaq: HGSI) back in August 2010. Despite the seemingly rich offer -- Human Genome's stock peaked at about $32.50 -- the $7 billion bid was rejected.
Today, Amgen is ticking higher following stronger-than-expected results for its second quarter, EPS of $1.83 beating views by 29 cents. Product sales rose 8 percent and its pipeline is in shipshape. In fact, shares are up a minimum of 44 percent since 2010, while Human Genome stock has fallen 56 percent over the same span.
Last week, Human Genome finally caved, agreeing to a $14.25 per share deal with GlaxoSmithKline (NYSE: GSK), which values the company at about $3 billion, or far less than what it would have received from Amgen.
Hindsight is 20/2, though. Human Genome had Benlysta in the works, which it hoped would propel the company to new heights. FDA approval in March 2011 led to paltry sales and a drop in Human Genome shares.
With the latest takeover, Human Genome invited Amgen to make a bid...but to no avail.
Amgen shares are about 4 percent higher in early trading, while Human Genome is flat.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UPDATE: Bausch & Lomb near deal to sell to Valeant Pharmaceuticals (VRX) - WSJ
- UPDATE: Intuit, Inc. (INTU) Tops Q3 EPS by 4c, Offers Guidance
- Abercrombie & Fitch Co. (ANF) Misses Q1 EPS by 4c; Guides FY Below Views
Create E-mail Alert Related Categories
Mergers and AcquisitionsRelated Entities
Earnings
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
